NCT03538028已完成1 期
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 8
- 主要终点
- Number of treatment-emergent adverse events (TEAEs)
研究概览
简要总结
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
- •Disease progression after treatment with available therapies that are known to confer clinical benefit, or intolerant to treatment, or refuse noncurative standard treatment. There is no limit to the number of prior treatment regimens.
- •Participants with advanced or metastatic cervical cancer, MSI-high endometrial cancer, gastric cancer (including stomach and GEJ), esophageal cancer, hepatocellular carcinoma, melanoma (uveal melanoma excluded), Merkel cell carcinoma, mesothelioma, MSI-high colorectal cancer, NSCLC, ovarian cancer, SCCHN, SCLC, RCC, triple-negative breast cancer, and urothelial carcinoma, or alternative immunogenic tumor types with medical monitor approval. Participants with DLBCL may participate in Part 2 of the study.
- •Presence of measureable disease based on RECIST v1.1 for solid tumors or the Lugano classification for DLBCL.
- •Willingness and ability to safely undergo pretreatment and on-treatment tumor biopsies.
- •Eastern Cooperative Oncology Group performance status 0 or 1.
排除标准
- •Laboratory and medical history parameters outside the protocol-defined range.
- •Transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before study Day
- •Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
- •Receipt of a live vaccine within 30 days of planned start of study drug.
- •Active autoimmune disease that required systemic treatment in the past.
- •Known active CNS metastases and/or carcinomatous meningitis.
- •Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry. See protocol-defined exceptions.
- •Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
- •Active infection requiring systemic therapy.
- •Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
- •Known history of HIV (HIV 1/2 antibodies).
- •Prior treatment with an anti-LAG-3 antibody for any indication.
结局指标
主要结局
Number of treatment-emergent adverse events (TEAEs)
时间窗: Up to 12 months
TEAE defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.
次要结局
- Cmax of INCAGN02385(Up to 12 months)
- Tmax of INCAGN02385(Up to 12 months)
- Objective response rate (ORR) in participants with advanced or metastatic solid tumors(Up to 12 months)
- Disease control rate (DCR) in participants with advanced or metastatic solid tumors(Up to 12 months)
- Cmin of INCAGN02385(Up to 12 months)
- AUC0-t of INCAGN02385(Up to 12 months)
- Duration of response (DOR) in participants with advanced or metastatic solid tumors(Up to 12 months)
- Progression-free survival (PFS) in participants with advanced or metastatic solid tumors(Up to 12 months)
- ORR in participants with diffuse large B-cell lymphoma (DLBCL)(Up to 12 months)
- DOR in participants with DLBCL(Up to 12 months)
- PFS in participants with DLBCL(Up to 12 months)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesGastroesophageal Junction CancerUveal MelanomaHepatocellular CarcinomaGastric CancerMelanomaCervical CancerEsophageal CancerMesotheliomaMSISquamous Cell Carcinoma of the Head and NeckUrothelial CarcinomaOvarian CancerNon-small Cell Lung CancerRCCMismatch Repair DeficiencyRenal Cell CarcinomaNSCLCStomach CancerTriple-negative Breast CancerSmall Cell Lung CancerMerkel Cell CarcinomaNCT03652077Incyte Corporation40
Unknown
1 期
Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBCUrinary Bladder NeoplasmsNCT04819399Lindis Biotech GmbH30
招募中
1 期
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsMyeloproliferative NeoplasmsNCT06034002Incyte Corporation290
进行中（未招募）
1 期
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsMyeloproliferative NeoplasmsNCT05936359Incyte Corporation160
已完成
1 期
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid TumorsAdvanced MalignanciesMetastatic CancerNCT02923349Incyte Biosciences International Sàrl87